Graf Acquisition Corp. IV (GFOR) to Combine with NKGen Biotech in $160M Deal

Graf Acquisition Corp. IV (NYSE:GFOR) has entered into a definitive agreement to combine with clinical-stage biotech company NKGen at an enterprise value of $160 million. Santa Ana, California-based NKGen has five pharmaceutical formulas that have each reached some stage of Phase I and Phase II clinical trials seeking potential therapies for cancer and neurodegenerative conditions
Read More